CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Sephience (sepiapterin) — coverage criteria for sepiapterin‑responsive PKU

Covers use of Sephience (sepiapterin) for treatment of sepiapterin‑responsive phenylketonuria (HPA/PKU) in members aged ≥1 month when approval criteria are met; governs prior authorization, coverage duration, and clinical criteria for Neighborhood Health Plan of Rhode Island members.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicySephience (sepiapterin) — coverage criteria for sepiapterin‑responsive PKU

Policy CodePolicy N/A

Change TypeNo material change

Effective Date02/2026

Next Review Date11/2025

Key ActionObtain prior authorization with documentation of diagnosis, baseline and historical phenylalanine measurements, weight, renal function, and prior sapropterin trial.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

1 monthminimum eligible age

2 monthsinitial authorization

6 monthsrenewal authorization

≥360baseline Phe threshold

≥2 ≥600required past Phe history

≤60 mg/kgmax dose

Coverage Criteria for Sephience (sepiapterin)

Initial Therapy

Covered when ALL of the following are met:

Initial authorization criteria: A. The medication is prescribed by, or in consultation with, a physician who specializes in the treatment of metabolic disease and/or phenylketonuria (PKU).

Initial authorization criteria: B. Member is one month of age or older.

Initial authorization criteria: C. Member has been diagnosed with phenylketonuria and meets both of the following: 1) Past medical history of at least 2 blood phenylalanine measurements ≥600 μmol/L; AND 2) Baseline phenylalanine level ≥360 μmol/L prior to starting treatment with the requested medication.

Initial authorization criteria:

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicySephience (sepiapterin) — coverage criteria for sepiapterin‑responsive PKU

Policy CodePolicy N/A

Change TypeNo material change

Effective Date02/2026

Next Review Date11/2025

Key ActionObtain prior authorization with documentation of diagnosis, baseline and historical phenylalanine measurements, weight, renal function, and prior sapropterin trial.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

D. Member has not been diagnosed with hyperphenylalaninemia due to pathogenic variants in GCH1, PTS, QDPR, SPR, or PCBD1 (i.e., not primary BH4 deficiency).

Initial authorization criteria: E. Documentation that the member does not have signs or laboratory findings of renal disease, including calculated GFR ≥60 mL/min/1.73 m2.GFR ≥60 mL/min/1.73 m2

Initial authorization criteria: F. The requested medication will be used in conjunction with a phenylalanine‑restricted diet.

Initial authorization criteria: G. Documentation that the requested medication will not be used in combination with sapropterin products (e.g., Javygtor, Kuvan) or pegvaliase (Palynziq).

Initial authorization criteria: H. Documentation of the member's most recent weight.

Initial authorization criteria: I. Medication is prescribed at the appropriate FDA‑approved weight‑based dose and does not exceed 60 mg/kg.Dose ≤60 mg/kg

Initial authorization criteria: J. Member has had a documented inadequate treatment response or intolerance to a formulary sapropterin product (inadequate response defined as blood Phe ≥360 μmol/L despite consistent use with dietary Phe restriction).Baseline Phe ≥360 μmol/L; prior history ≥2 measures ≥600 μmol/L

Initial approval duration: 2 months

Renewal Therapy

Covered when ALL of the following are met:

Renewal criteria: A. Member continues to meet all initial criteria.

Renewal criteria: B. Chart notes or medical records demonstrate achievement or maintenance of at least one of the following: 1) ≥30% decrease in phenylalanine levels from baseline; OR 2) Phenylalanine level <360 μmol/L; OR 3) Improvement in neuropsychiatric symptoms.Response: ≥30% Phe decrease or Phe <360 μmol/L

Renewal authorization duration: 6 months

All indications for Sephience (sepiapterin) other than the FDA‑approved indication—treatment of sepiapterin‑responsive hyperphenylalaninemia/phenylketonuria (HPA/PKU) in patients aged 1 month or older when used as an adjunct to a phenylalanine‑restricted diet—are considered experimental/investigational and not medically necessary. Requests for treatment of conditions outside this indication will be denied.

Use of Sephience (sepiapterin) for any indication other than sepiapterin‑responsive HPA/PKU in patients aged 1 month and older, as specified in the FDA‑approved labeling, is not medically necessary and will not be covered.

Clinical Thresholds, Dosing, and Lab Requirements

Phenylalanine (Phe) levels

Baseline phenylalanine (Phe)Baseline Phe ≥360 μmol/L prior to starting therapy

Historical Phe measurementsPast medical history of at least 2 blood Phe measurements ≥600 μmol/L

Renewal response criteriaRenewal requires either ≥30% decrease in Phe from baseline or Phe <360 μmol/L (or clinical improvement in neuropsychiatric symptoms)

Estimated GFR

Minimum renal functionCalculated GFR ≥60 mL/min/1.73 m2 required

Documentation requirementDocumentation that member has no signs/symptoms of renal disease and GFR is ≥60 mL/min/1.73 m2

Exclusion triggerGFR <60 mL/min/1.73 m2 is indicative of renal disease and does not meet authorization criteria

Maximum dose

Maximum weight‑based doseDose must not exceed 60 mg/kg

FDA‑approved dosingMedication must be prescribed at the appropriate FDA‑approved dose based on the member's weight

Documentation requirementProvider must document the member's most recent weight to confirm dosing

Prior Authorization, Documentation, and Denial Conditions

Prior Authorization

Prior Authorization Required

Prior authorization is required. Initial approvals may be granted for 2 months; renewals may be granted for 6 months when continuation criteria are met.

Initial approval duration: 2 months
Renewal approval duration: 6 months when renewal criteria are satisfied

Step Therapy

Step Therapy Requirement

Member must have had a documented inadequate response or intolerance to a formulary sapropterin product prior to approval. Inadequate response is defined as blood phenylalanine (Phe) ≥360 μmol/L despite consistent use in combination with dietary Phe restriction.

Step therapy requirement: trial of formulary sapropterin with documented inadequate response or intolerance
Definition of inadequate response: Phe ≥360 μmol/L despite compliant use plus Phe-restricted diet

Documentation Required

Documentation Required at Submission

Submit clinical notes or medical records documenting diagnosis and required laboratory values. At minimum include: prior Phe measurements (at least two historical measurements ≥600 μmol/L), a baseline Phe measurement ≥360 μmol/L prior to starting treatment, documentation of the member’s most recent weight, and documentation that the medication will be used with a Phe‑restricted diet.

Required documentation: ≥2 historical blood Phe measurements ≥600 μmol/L
Baseline Phe ≥360 μmol/L prior to treatment start
Member’s most recent weight
Plan to use medication with a Phe‑restricted diet

Documentation Required

Renewal Documentation

For renewal requests, provide chart notes or medical records demonstrating clinical benefit: either a ≥30% decrease in Phe from baseline, Phe <360 μmol/L, or improvement in neuropsychiatric symptoms.

Renewal documentation: ≥30% reduction in Phe from baseline OR Phe <360 μmol/L OR documented improvement in neuropsychiatric symptoms

Denial Risk

Indication Limitations

Use for indications other than FDA‑approved sepiapterin‑responsive HPA/PKU (in patients ≥1 month of age) is considered experimental/investigational and not medically necessary.

Indication limited to sepiapterin‑responsive hyperphenylalaninemia (HPA)/PKU in patients ≥1 month old and used with a Phe‑restricted diet
All other indications: experimental/investigational — not medically necessary

Denial Risk

Concurrent Prohibited Therapies

Concurrent use with sapropterin products (e.g., sapropterin, Javygtor, Kuvan) or pegvaliase (Palynziq) is prohibited and may result in denial.

Do not prescribe in combination with sapropterin products or Palynziq (pegvaliase-pqpz)
Concurrent therapy with these agents may trigger claim denial

Denial Risk

Insufficient Laboratory or Prescriber Documentation

Failure to document required laboratory values (baseline and prior Phe measurements meeting thresholds) or specialist prescribing/consultation may lead to denial for insufficient documentation.

Insufficient lab documentation: missing baseline Phe ≥360 μmol/L or fewer than two historical Phe ≥600 μmol/L
Prescriber requirement: prescribed by or in consultation with a physician specializing in metabolic disease/PKU

Background

Sephience (sepiapterin) is indicated, per FDA labeling, as an adjunct to a phenylalanine‑restricted diet for the treatment of sepiapterin‑responsive hyperphenylalaninemia/phenylketonuria (HPA/PKU) in adult and pediatric patients aged 1 month and older. Therapy should be used with dietary Phe restriction; use for other diagnoses is considered experimental/investigational and not medically necessary.

Definitions and Diagnostic Exclusions

Inadequate response to sapropterin

Definition of inadequate response to sapropterinBlood phenylalanine ≥360 μmol/L despite consistent use of sapropterin in combination with dietary Phe restriction

Context for step therapyDocumented inadequate response or intolerance to a formulary sapropterin product is required prior to approval

Evidence requiredClinical records should show persistent Phe ≥360 μmol/L while on sapropterin plus Phe‑restricted diet

Primary BH4 deficiency exclusion

Exclusion of primary BH4 deficiencyMember must not have hyperphenylalaninemia due to pathogenic variants in GCH1, PTS, QDPR, SPR, or PCBD1

Documentation neededMedical record must indicate absence of a diagnosis of primary BH4 deficiency (no pathogenic variants in listed genes)

Impact on eligibilityA diagnosis of primary BH4 deficiency (pathogenic variants in these genes) excludes the member from coverage under these criteria